Effects of Bone Marrow–Derived Mononuclear Cells From Healthy or Acute Respiratory Distress Syndrome Donors on Recipient Lung-Injured Mice

Silva, Johnatas D.; Paredes, Bruno; Araújo, Indianara Maria; Lopes‐Pacheco, Miquéias; Oliveira, Milena V.; Suhett, Grazielle; Faccioli, Lanuza A. P.; Assis, Edson F. de; Castro‐Faria‐Neto, Hugo C.; Goldenberg, Regina Coeli dos Santos; Capelozzi, Vera Luíza; Morales, Marcelo M.; Pelosi, Paolo; Xisto, Débora G.; Rocco, Patrícia Rieken Macêdo

doi:10.1097/ccm.0000000000000296

Cited by 24 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have reported that the response to pharmacological therapies might differ depending on the primary insult [17,24,32]. The experimental models of pulmonary and extrapulmonary ARDS used herein were induced by intratracheal or intraperitoneal injection of Escherichia coli LPS, respectively, and resulted in similar degrees of lung mechanical changes at days 1 [18][19][20] and 2 [19]. In the present study, ARDSp and ARDSexp animals treated with DMSO exhibited increases in Est,L and DAD score, as well as neutrophil infiltration, compared to the C-DMSO group.…”

Section: Discussionmentioning

confidence: 99%

“…The dose of LPS was selected based on previous studies demonstrating similar mechanical and morphometrical compromise in ARDSp and ARDSexp C57/BL6 mice [18][19][20]. At two time points after pre-treatment (6h and 24h), DMSO, dasatinib 1 mg/kg, or dasatinib 10 mg/ kg were given again as appropriate per group allocation.…”

Section: Animal Preparation and Experimental Protocolmentioning

confidence: 99%

“…The mice were kept under specific pathogen-free conditions, maintained without physical activities, on a 12:12 h light-dark cycle, at controlled temperature (20)(21)(22) o C), and had unrestricted access to food and water. Initially, all mice were randomly divided to be pre-treated with vehicle (dimethyl sulfoxide [DMSO] 1% in saline solution, 100 µL, by oral gavage) or dasatinib, which was administered in two different doses (1 mg/kg body weight [BW] or 10 mg/kg BW, diluted in 1% DMSO, 100 µL by oral gavage).…”

Section: Animal Preparation and Experimental Protocolmentioning

confidence: 99%

“…The supernatant was stored at -80°C for cytokine analysis. Differential cell counts were performed in Cytospin smears stained by the May-Grünwald-Giemsa method [20]. Total leukocyte numbers were measured in a Neubauer chamber under light microscopy after diluting the samples in Türk solution (2% acetic acid).…”

Section: Evaluation Of Bronchoalveolar Lavage Fluidmentioning

confidence: 99%

See 3 more Smart Citations

The Effects of Dasatinib in Experimental Acute Respiratory Distress Syndrome Depend on Dose and Etiology

Oliveira

Silva

Marques

et al. 2015

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: Evidence suggests that tyrosine-kinase inhibitors may attenuate lung inflammation and fibrosis in experimental acute respiratory distress syndrome (ARDS). We hypothesized that dasatinib, a tyrosine-kinase inhibitor, might act differently depending on the ARDS etiology and the dose. Methods: C57/BL6 mice were divided to be pre-treated with dasatinib (1mg/kg or 10mg/kg) or vehicle (1% dimethyl-sulfoxide) by oral gavage. Thirty-minutes after pre-treatment, mice were subdivided into control (C) or ARDS groups. ARDS animals received Escherichia coli lipopolysaccharide intratracheally (ARDSp) or intraperitoneally (ARDSexp). A new dose of dasatinib or vehicle was administered at 6 and 24h. Results: Forty-eight hours after ARDS induction, dasatinib 1mg/kg yielded: improved lung morphofunction and reduced cells expressing toll-like receptor (TLR)-4 in lung, independent of ARDS etiology; reduced neutrophil and levels of interleukin (IL)-6, IL-10 and transforming growth factor (TGF)-β in ARDSp. The higher dose of dasatinib caused no changes in lung mechanics, diffuse alveolar damage, neutrophil, or cells expressing TLR4, but increased IL-6, vascular endothelial growth factor (VEGF), and cells expressing Fas receptor in lung in ARDSp. In ARDSexp, it improved lung morphofunction, increased VEGF, and reduced cells expressing TLR4. Conclusion: Dasatinib may have therapeutic potential in ARDS independent of etiology, but careful dose monitoring is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Animal Preparation and Experimental Protocolmentioning

confidence: 99%

Section: Animal Preparation and Experimental Protocolmentioning

confidence: 99%

Section: Evaluation Of Bronchoalveolar Lavage Fluidmentioning

confidence: 99%

See 2 more Smart Citations

The Effects of Dasatinib in Experimental Acute Respiratory Distress Syndrome Depend on Dose and Etiology

Oliveira

Silva

Marques

et al. 2015

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar findings were observed in an animal model of acute lung injury [26, 57]. As such, there may be instances in which autologous BMDMCs obtained from individuals with a given lung disease may be appropriate [26, 57]. Furthermore, it is imperative to understand which cell populations in the BMDMCs might convey beneficial effects for use in any given disease.…”

Section: Discussionmentioning

confidence: 56%

CD11b+ and Sca-1+ Cells Exert the Main Beneficial Effects of Systemically Administered Bone Marrow-Derived Mononuclear Cells in a Murine Model of Mixed Th2/Th17 Allergic Airway Inflammation

Cruz

Borg

Goodwin

et al. 2016

Stem Cells Translational Medicine

View full text Add to dashboard Cite

A murine model of severe clinical asthma was used to study which bone marrow-derived mononuclear cells (BMDMCs) are responsible for ameliorating airway hyperresponsiveness and lung inflammation. BMDMCs depleted of either CD11b-positive cells (monocytes, macrophages, dendritic cells) or Sca-1-positive cells (bone marrow-derived mesenchymal stromal cells) were unable to ameliorate these conditions in this model. Depletion of the other cell types did not diminish the ameliorating effects of BMDMC administration.

show abstract

Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome

et al. 2019

Self Cite

View full text Add to dashboard Cite

The acute respiratory distress syndrome (ARDS) is a multifaceted lung disorder in which no specific therapeutic intervention is able to effectively improve clinical outcomes. Despite an improved understanding of molecular mechanisms and advances in supportive care strategies, ARDS remains associated with high mortality, and survivors usually face longterm morbidity. In recent years, preclinical studies have provided mounting evidence of the potential of mesenchymal stem cell (MSC)-based therapies in lung diseases and critical illnesses. In several models of ARDS, MSCs have been demonstrated to induce antiinflammatory and anti-apoptotic effects, improve epithelial and endothelial cell recovery, and enhance microbial and alveolar fluid clearance, thus resulting in improved lung and distal organ function and survival. Early-stage clinical trials have also demonstrated the safety of MSC administration in patients with ARDS, but further, large-scale investigations are required to assess the safety and efficacy profile of these therapies. In this review, we summarize the main mechanisms whereby MSCs have been shown to exert therapeutic effects in experimental ARDS. We also highlight questions that need to be further elucidated and barriers that must be overcome in order to efficiently translate MSC research into clinical practice.

show abstract

Effects of Bone Marrow–Derived Mononuclear Cells From Healthy or Acute Respiratory Distress Syndrome Donors on Recipient Lung-Injured Mice

Cited by 24 publications

References 25 publications

The Effects of Dasatinib in Experimental Acute Respiratory Distress Syndrome Depend on Dose and Etiology

The Effects of Dasatinib in Experimental Acute Respiratory Distress Syndrome Depend on Dose and Etiology

CD11b+ and Sca-1+ Cells Exert the Main Beneficial Effects of Systemically Administered Bone Marrow-Derived Mononuclear Cells in a Murine Model of Mixed Th2/Th17 Allergic Airway Inflammation

Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome

Contact Info

Product

Resources

About